返回 Agenda
Session 6: Innovative Business Models For Pediatric Therapeutic Development
Session Chair(s)
Thomas Miller, PhD
Vice President and Global Head, Pediatrics
Bayer, United States
Christina Bucci-Rechtweg, MD
Global Head, Maternal Health and Pediatric Regulatory Policy
Novartis , United States
In recent years, deliberate prioritization of medication development for children has accelerated broadly across the life sciences ecosystem. This session will explore evolving, innovative business models for pediatric therapeutics. Presentations will focus on the increasingly important role of key stakeholders including large pharma, venture capital, and new academic medical center business models relating to pediatric therapeutics development. Presentations will be followed by an engaging panel discussion.
Learning Objective : At the conclusion of this session, participants should be able to:- Gain the growing role of pediatric therapeutics development in the life sciences ecosystem
- Understand how companies make decisions regarding inclusion of pediatric development programs within their portfolios
- Understand the unique, evolving and important roles of large Pharma, Venture Capital, and Academic Institutions play towards the advancement of new medications for children
Speaker(s)
Pharma Portfolio Considerations for Pediatric Development Programs
Thomas Miller, PhD
Bayer, United States
Vice President and Global Head, Pediatrics
TRINITY Whitepaper: What We Value – the Proposition Behind the Price
Gavin Miyasato, MS
TRINITY, United States
Associate Director of Statistics
Redefining the Approach for Pediatric Academic Medical Centers
Daniel Fields, JD
Children’s Hospital of Philadelphia, United States
Vice President, Business Innovation